AlphaStocks
4.3
Weak

TransMedics Group, Inc. (TMDX)

Health Care / Health Care Equipment

S&P SmallCap 600

$100.52

Below average on several measures. Research carefully.

Weak

Score based on 4 of 5 models — moderate confidence

#782out of 1127 in Health Care

Is TransMedics Group, Inc. a Good Investment in 2026?

TransMedics Group, Inc. (TMDX) scores 4.3 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Piotroski model rates TransMedics Group, Inc. as Attractive (5/9). However, the Graham model rates it Caution — Significantly above fair value. TransMedics Group, Inc. currently trades below its estimated fair value of $136, suggesting potential upside. TransMedics Group, Inc. ranks #782 out of 1127 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E21.4ROE25.6Market Cap3B

Estimated Fair Value

$136.0326% below

Fair value above market price. EPS grew 366% year-over-year. ROE of 26% signals strong profitability. P/E of 21x is moderate for this quality level.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Attractive

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Limited Data

Growth rate vs price (PEG)

Greenblatt

Neutral

Bottom half (rank 65%)

Frequently Asked Questions

Is TransMedics Group, Inc. (TMDX) a good investment?
Based on AlphaStocks' composite analysis, TransMedics Group, Inc. (TMDX) scores 4.3 out of 10, earning a Weak rating. This score is below average, suggesting caution. Fair value above market price. EPS grew 366% year-over-year. ROE of 26% signals strong profitability. P/E of 21x is moderate for this quality level.
What is TransMedics Group, Inc.'s Piotroski F-Score?
TransMedics Group, Inc.'s Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is TMDX overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $136, TMDX appears undervalued. The stock currently trades 26% below its estimated fair value. Fair value above market price. EPS grew 366% year-over-year. ROE of 26% signals strong profitability. P/E of 21x is moderate for this quality level.
How does TMDX compare to other Health Care stocks?
TransMedics Group, Inc. ranks #782 out of 1127 stocks in the Health Care sector, placing it in the top 69% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about TMDX?
AlphaStocks evaluates TMDX using five proven investment models. Piotroski: Attractive; Buffett: Attractive; Graham: Caution; Greenblatt Magic Formula: Neutral. These models are combined into a single composite score of 4.3/10.

Similar Stocks

PARRFTIAZN

Compare TMDX with

TMDX vs PARRTMDX vs FTITMDX vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer